Stocks and Investing
Stocks and Investing
Fri, September 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Geoff Meacham Downgraded (VIR) to Hold and Decreased Target to $14 on, Sep 8th, 2023
Geoff Meacham of B of A Securities, Downgraded "Vir Biotechnology, Inc." (VIR) to Hold and Decreased Target from $23 to $14 on, Sep 8th, 2023.
Geoff has made no other calls on VIR in the last 4 months.
There are 5 other peers that have a rating on VIR. Out of the 5 peers that are also analyzing VIR, 1 agrees with Geoff's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Michelle Gilson of "Morgan Stanley" Maintained at Hold with Decreased Target to $15 on, Friday, July 21st, 2023
These are the ratings of the 4 analyists that currently disagree with Geoff
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $95 on, Monday, August 7th, 2023
- Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $22 on, Friday, August 4th, 2023
- Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $28 on, Friday, July 21st, 2023
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $41 on, Friday, July 21st, 2023
Contributing Sources